Cibus director Gerhard Prante sells $2,691 in stock

Cibus, Inc., based in San Diego, operates in the agriculture chemicals industry, contributing to advancements in agricultural applications and services. While the company showed impressive revenue growth of over 449% in the last twelve months, InvestingPro subscribers can access 12 additional key insights about CBUS's financial performance and market position. While the company showed impressive revenue growth of over 449% in the last twelve months, InvestingPro subscribers can access 12 additional key insights about CBUS's financial performance and market position.

Cibus, Inc., based in San Diego, operates in the agriculture chemicals industry, contributing to advancements in agricultural applications and services. While the company showed impressive revenue growth of over 449% in the last twelve months, InvestingPro subscribers can access 12 additional key insights about CBUS's financial performance and market position.

Cibus, Inc., based in San Diego, operates in the agriculture chemicals industry, contributing to advancements in agricultural applications and services.

In other recent news, Cibus Inc. has reported a significant net loss of $201.5 million, primarily due to an impairment of goodwill. Despite this, the company anticipates earning $200 million annually in royalties from rice traits in the U.S. and an additional $150 million from expansion into Asian markets. The agricultural gene editing firm is also planning to launch herbicide-resistant and Pod Shatter Reduction traits, targeting significant market opportunities in the U.S., Latin America, and Asia.

On the executive front, Cibus has approved a new base salary of $320,000 for Carlo Broos, a key member of the management team. The decision, recorded in the company's 8-K report, reflects a change in the compensation arrangement.

In terms of financial analysis, Jefferies has adjusted its price target for Cibus, reducing it to $5.00 from the previous $8.00, while maintaining its Hold rating on the stock. This decision comes as Cibus is noted for carefully managing its balance sheet, focusing on maintaining the quality of its royalty economics.

These developments indicate Cibus's ongoing efforts to enhance agricultural productivity and sustainability through gene editing, despite facing financial losses. The company's executives have expressed confidence in the efficiency of the Trait Machine and the protoplast regeneration method, and they are exploring sustainable ingredients and fragrances, with announcements expected by next year.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.